Pilgrim

Pilgrim is a defense biotechnology company based in Redwood City, California, that develops, validates, and deploys battlefield-ready biotechnology for national security. Its stated goal is to become America's biology prime. Work spans biology, biotechnology, chemistry, and mechanical, electrical, and autonomous systems engineering, with an explicit emphasis on moving past theory to field-tested, deployable capability for military personnel operating in demanding environments.

The company's most relevant system for robotics and autonomy engineers is ARGUS, a fully autonomous platform designed to detect biological threats in near real time. The detection scope covers both naturally occurring pathogens and engineered agents. The product is built around autonomous operation, which implies work at the intersection of biosensing hardware, embedded electronics, and the control and signal-processing software that closes the loop from sample to detection without operator intervention.

Alongside ARGUS, Pilgrim develops hemostatic dressings supporting military medicine and, in part, civilian applications. Engineering domains in play across the portfolio include biological threat detection, biosensing, military medicine, hemostatics, and autonomous systems.

Pilgrim has raised $7.55 million to date: $3.25 million in pre-seed funding and $4.3 million in a seed round. Investors include Peter Thiel, Brian Armstrong, Fred Ehrsam, and Dylan Field.